Skip to main content

Table 1 Clinical characteristics stratified by the timing of selective immunosuppressive therapy initiation (SIT)

From: Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis

Covariate

≤ 10 days of onset

N = 44

> 10 days of onset

N = 40

P

ICI type, No. (%)

  

0.687

Anti-CTLA-4 monotherapy

11 (25)

10 (25)

 

Anti-PD-1/L1 monotherapy

19 (43)

14 (35)

 

Combination

14 (32)

16 (40)

 

Diarrhea grade, No. (%)

  

0.668

1–2

8 (18)

6 (15)

 

3

28 (64)

29 (73)

 

4

8 (18)

5 (13)

 

Colitis grade, No. (%)

  

0.603

1–2

24 (56)

22 (55)

 

3

16 (37)

17 (43)

 

4

3 (7)

1 (3)

 

Endoscopic features, No. (%)

  

0.739

Ulcer

13 (42)

17 (52)

 

Non-ulcerative inflammation

12 (39)

11 (33)

 

Normal

6 (19)

5 (15)

 

High-risk endoscopic features initially, No. (%)a

17 (55)

23 (70)

0.302

Overall duration of steroids, mean days (SD)

64 (38)

82 (51)

0.092

Duration of hospitalization, mean days (SD)

10 (8)

12 (8)

0.321

Duration of symptoms, mean days (SD)

25 (32)

50 (40)

0.002

Follow-up duration, mean months (SD)

5 (3)

4 (3)

0.875

Number of steroids tapering attempts, median (IQR)

1 (1–4)

2 (1–4)

< 0.001

Multiple hospitalization, No. (%)

13 (30)

22 (55)

0.026

Failed steroid tapering after SIT, No. (%)b

9 (23)

19 (49)

0.033

Recurrent IMC, No. (%)

8 (18)

8 (20)

1.000

Infectious adverse events, No. (%)

16 (36)

9 (23)

0.233

  1. aHigh-risk features are ulcers deeper than 2 mm or wider than 1 cm, and extensive endoscopic inflammation involving the colon proximal to the splenic flexure
  2. bAvailable for the 79 patients who received steroids
  3. Abbreviation: SIT, selective immunosuppressive therapy